Xingjun Meng^1,#, Zhihui Cao^2,#, Renfeng Liu^3,#, Kai Zheng⁴, Shuai Ding⁵, Yuefan Gu⁴, Yonghua Chen⁶, Jun Lv⁷, Ping Li⁸, Li Zhou⁹, Wenbo Wang¹⁰, Shiliang Ji¹¹, Hui He^12,*, Hui Yang^9,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.021259

Abstract It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor progression, we chose paclitaxel and… More >

Robabeh Faghani Baladehi^1,2, Mohammad Yousef Memar¹, Abolfazl Jafari Sales³, Ahad Bazmani^1,4, Javid Sadri Nahand^1,5,6, Parisa Shiri Aghbash^2,7, Hossein Bannazadeh Baghi^1,2,7,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.020648

Abstract The ability of host cells to activate apoptosis is perhaps the most potent weapon for helping cells eliminate viruses. Human papillomaviruses (HPV) activate several pathways, enabling the infected cells to avoid extrinsic and intrinsic apoptosis pathways. The incapacity of prostatic epithelial cells to induce apoptosis leads to the invasive development of prostate cancer. For the pathogenesis of prostate cancer, several risk factors have been reported; for example, some viruses and infectious diseases have been proposed as causative agents for their relation to prostate diseases. According to several studies, high-risk human papillomaviruses cause malignancy by interfering with the apoptotic and inflammatory… More >

Giuseppe Emmanuele Umana^1,*, Gianluca Ferini², Antonio Crea¹, Bipin Chaurasia³, Vishal Chavda⁴, Leonardo Corbino¹, Daniele Franceschini¹, Maria Grazia Tranchina⁵, Marco Fricia¹, Francesca Graziano⁶, Giovanni Federico Nicoletti⁶, Salvatore Cicero¹, Gianluca Scalia⁶

Oncologie, Vol., , DOI:10.32604/oncologie.2022.021347

Abstract Concomitant acute epidural hematoma (EDH) and subdural hematoma (SDH) is a rare finding, and its bilateral onset has not yet been reported in literature. We present the first report of a patient affected by post-traumatic concomitant EDH and SDH, with the contralateral, delayed onset of another, associated with meningioma previously treated with gamma knife. A 60-year-old female patient with a history of simple focal seizures with motor symptoms and well-controlled by drugs since childhood, arterial hypertension, and incidental diagnosis of multiple meningiomas was referred to our department after falling down the stairs. Initially, the patient was prescribed gamma knife treatment… More >

Ollo Roland Somé^1,*, Abdoul Halim Bagué², Damien Konkobo¹, Dieudonné Hien³, Adama Dembélé³, GL Hermann Bélemlilga¹, Valentin Konségré⁴, Nayi Zongo⁵

Oncologie, Vol., , DOI:10.32604/oncologie.2022.021250

Abstract Introduction: Breast cancer management in Sub-Saharian Africa, is faced with diagnosis and treatment challenges. This study aims to describe, breast cancers epidemiology in Bobo-Dioulasso, Burkina Faso. Patients and method: A retrospective cohort study was performed from July 01, 2015 to December 31, 2021 in the Souro Sanou university teaching hospital. Histologically confirmed breast cancer patients were included. Clinical aspect, treatment features and outcome data were collected and analyzed. Results: In study time, eight male’s cases (2%) 360 female’s cases among 368 breast cancers cases were included. The mean age was 46.6 ± 12.1 years, ranging from 15 to 90. The… More >

Hao Luo^1,#,*, Yanjie Ji^2,#, Xinrong Gao¹, Xinying Liu¹, Yunzhao Wu³, Yingli Wu^3,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.021705

Abstract The ubiquitin-proteasome system (UPS) is an important pathway for cellular protein degradation. The components of this pathway, including the proteasome, ubiquitinase, and deubiquitinase, are highly specialized and strictly regulated. The ubiquitin-specific protease 2 (USP2) belongs to the ubiquitin-specific proteases, a subgroup of deubiquitinating enzymes. USP2 plays essential roles in regulating cell survival, cell cycle, circadian rhythm, cell metabolism, inflammatory response, antiviral response, and metastasis by interacting with certain proteins such as Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR1-TGFBR2 complex. Elevation of USP2 has been observed in a variety of cancers, including glioma, testicular cancer, breast cancer,… More >

Beifen Dai^1,#, Zhihao Xu^2,#, Hongjue Li³, Bo Wang³, Jinsong Cai¹, Xiaomo Liu^4,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.020259

Abstract Large-scale genomic studies are important ways to comprehensively decode the human genomics, and provide valuable insights to human disease causalities and phenotype developments. Genomic studies are in need of high throughput bioinformatics analyses to harness and integrate such big data. It is in this overarching context that artificial intelligence (AI) offers enormous potentials to advance genomic studies. However, racial bias is always an important issue in the data. It is usually due to the accumulation process of the dataset that inevitability involved diverse subjects with different races. How can race bias affect the outcomes of AI methods? In this work,… More >

Dong Yan^1,#, Chunxiao Li^2,#, Yantong Zhou², Xue Yan¹, Weihua Zhi¹, Haili Qian^2,*, Yue Han^1,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.020357

Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results revealed that… More >

Jiayi Huang¹, Xue Bai¹, Xiaofeng Xie¹, Liping Chen¹, Xiaofeng Lan¹, Qiuyi Zhang¹, Lin Song¹, Pengjiao Hong^2,3, Caiwen Du^1,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.019881

Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences… More >

Federico Cappellacci^*, Gian Luigi Canu, Stefano Piras, Giacomo Anedda, Pietro Giorgio Calò, Fabio Medas

Oncologie, Vol., , DOI:10.32604/oncologie.2022.020864

Abstract Thyroid cancer is the fifth most common cancer in the USA, with differentiated subtype accounting for more than 95% of neoplasm. Surgery remains the mainstay of treatment, either with lobectomy or total thyroidectomy. In the last decades, many technological innovations have been introduced in this field. The aim of this review is to illustrate the most recent advances regarding the classical surgical approach, particularly regarding hemostatic devices, parathyroid identification with fluorescence systems, intraoperative identification of lymph node metastases, and intraoperative neuromonitoring. More >

Hiba Alzoubi¹, Alameen Alsabbah², Rosario Caltabiano³, Giuseppe Broggi^3,*

Oncologie, Vol., , DOI:10.32604/oncologie.2022.020890

Abstract The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) improved our understanding of the brain neoplasm biology. In more details, differences between diffuse gliomas that primarily occur in adults and those that primarily occur in children have been identified by the terms “adult-type” and “pediatric-type” diffuse gliomas. More importantly, both diagnostic and grading criteria for adult-type diffuse astrocytomas have been modified, by adopting novel molecular markers: diffuse astrocytomas, IDH-mutant have been grouped into a single entity and graded as CNS WHO grades 2, 3, or 4, with the assignment of Grade 4 in the… More >